Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07360080 · ClinicalTrials.gov registry record
Long-Term Outcomes of Teplizumab in Routine Clinical Care
A clinical trial, sponsored by Sanofi.
- Recruiting
- Registry status
- 1,000
- Enrollment target
NCT07360080 is a clinical trial that is actively recruiting participants, run by Sanofi. The registered enrollment target is 1,000 participants.
The verdict
NCT07360080 is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
Study Summary
This is an observational, prospective cohort study designed to evaluate the outcomes after teplizumab treatment in participants with Stage 2 Type 1 Diabetes (T1D) for delaying the onset of Stage 3 T1D. The study will monitor participants receiving teplizumab as part of routine clinical care across multiple sites. Additionally, patient-reported outcomes (PROs) will be evaluated to further assess the treatment's impact on participant's quality of life including emotional and psychosocial aspects associated with T1D. This approach will provide a more comprehensive understanding of how the treatment performs over time and across diverse patient populations, providing valuable insights into the sustained effects of teplizumab and offering a real world picture of its impact on the long-term management of T1D.
Interventions
- DRUG Teplizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2026-03-19 |
| Est. Completion | 2035-10-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07360080
The ClinicalTrials.gov registry entry for NCT07360080 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Teplizumab is the first listed.
NCT07360080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07360080 about?
NCT07360080 is a clinical study titled "Long-Term Outcomes of Teplizumab in Routine Clinical Care". This is an observational, prospective cohort study designed to evaluate the outcomes after teplizumab treatment in participants with Stage 2 Type 1 Diabetes (T1D) for delaying the onset of Stage 3 T1D. The study will monitor participants receiving teplizumab as part of routine clinical care across m...
What is the current status of trial NCT07360080?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2026-03-19. Estimated completion is 2035-10-29.
What interventions are being tested in trial NCT07360080?
The interventions under investigation include: Teplizumab (DRUG).
Who is sponsoring clinical trial NCT07360080?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.